Rakesh Popat

7.9k citations

154 papers · 2.7k indexed · 1 hit paper · h-index 29

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology

Papers in

Hematology 134
- Multiple Myeloma Research and Treatments 129
Oncology 73
- Peptidase Inhibition and Analysis 26
- CAR-T cell therapy research 21
- Cancer Treatment and Pharmacology 15

Co-authors: Jamie Cavenagh Heather Oakervee Kwee Yong Joanna Opalinska Nicola Curry Curly Morris Dixie‐Lee Esseltine Mary Drake
Journals: Blood (53 papers)Journal of Clinical Oncology (22 papers)British Journal of Haematology (10 papers)HemaSphere (8 papers)Blood Cancer Journal (4 papers)
Partner nations: United Kingdom United States Spain

In The Last Decade

Rakesh Popat

132 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial 2020 · 256 citations

Peers

Countries citing papers authored by Rakesh Popat

Since Specialization

Citations

This map shows the geographic impact of Rakesh Popat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rakesh Popat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rakesh Popat more than expected).

Fields of papers citing papers by Rakesh Popat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rakesh Popat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rakesh Popat. The network helps show where Rakesh Popat may publish in the future.

Co-authors

The 25 scholars most cited alongside Rakesh Popat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rakesh Popat Line = papers co-authored together Rakesh Popat links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review Clinical Lymphoma Myeloma & Leukemia ·Shaji Kumar, Xavier Leleu, Katja Weisel, Rakesh Popat, Beatrice Suero, Samantha Craigie, Paul Spin, Leena Patel, Abril Oliva Ramirez, Christian Hampp, Wenzhen Ge, Qiufei Ma, Sundar Jagannath	2025	0
2	Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis Leukemia ·Hira Mian, Thomas G Martin, Gregory R. Pond, Sireesha Asoori, Rakesh Popat, Efstathios Kastritis, Joaquín Martínez‐López, Nadine Abdallah, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Meletios Α. Dimopoulos, Kwee Yong, Brian GM. Durie, Saad Z. Usmani, Yi Lin, Carlyn Tan	2025	1
3	Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience Haematologica ·Ke Xu, Charles Agbuduwe, Nikolaos Kanellias, William Wilson, Annabel McMillan, Xenofon Papanikolaou, Lydia Lee, Rakesh Popat, Jonathan Sive, Neil Rabin, Kwee Yong, Agapi Parcharidou, Charalampia Kyriakou	2024	0
4	Outcomes of melphalan 140 mg/m² followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience SHILAP Revista de lepidopterología ·Dario Melotti, Samir Asher, Ethan Troy‐Barnes, George Nesr, William Wilson, Marquita Camilleri, Rakesh Popat, Ke Xu, Neil Rabin, Jonathan Sive, Xenofon Papanikolaou, Lydia Lee, Annabel McMillan, Kwee Yong, Chara Kyriakou	2024	0
5	LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES Hematology Transfusion and Cell Therapy ·Luciano J. Costa, N. W. van de Donk, Laura Rosiñol, Rakesh Popat, Be semer, Joaquín Martínez‐López, D Trancucci, Tara Stephenson, Katherine Chastain, NJ Bahlis	2024	0
6	Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis. Journal of Clinical Oncology ·Nizar J. Bahlis, Rakesh Popat, Meral Beksaç, Meletios Α. Dimopoulos, Moshe E. Gatt, Francesca Gay, Jae‐Cheol Jo, Prashant Kapoor, K. Martin Kortüm, Silvia Ling, Chandramouli Nagarajan, Kenshi Suzuki, Maika Onishi, Monique Dail, Emily L. Rossi, Xizhi Luo, Emma Arriola, Orlando F. Bueno, Jeremy A. Ross, María‐Victoria Mateos	2024	5
7	Management of multiple myeloma presenting as malignant spinal cord compression during pregnancy: a case report PubMed ·Khushnuma Mullanfiroze, Charlotte Jones, David Williams, Matias C. Vieira, Ashutosh Wechalekar, Xenofon Papanikolaou, Rakesh Popat, Charalampia Kyriakou, Ke Xu	2024	0
8	Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma SHILAP Revista de lepidopterología ·Ke Xu, Eleanor Kaffo, Robert Baker, Elisabeth P. Nacheva, Annabel McMillan, Lydia Lee, Xenofon Papanikolaou, Rakesh Popat, Jonathan Sive, Kwee Yong, Neil Rabin, Charalampia Kyriakou, Rajeev Gupta	2024	0
9	Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium Blood ·Murali Janakiram, Carlyn Tan, Rakesh Popat, Joaquín Martínez‐López, Efstathios Kastritis, Chris Lau, Wee Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Roy Chowdhury, Yi Lin, Thomas G Martin, Amrita Krishnan	2024	0
10	Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic Blood Cancer Journal ·Jonathan Carmichael, Frances Seymour, Graham McIlroy, Sarrah Tayabali, Rosie Amerikanou, Sylvia Feyler, Rakesh Popat, Guy Pratt, Christopher Parrish, A. John Ashcroft, Graham Jackson, Gordon Cook	2023	8
11	Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis Blood Advances ·Gemma Reynolds, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin, Rakesh Popat, Shonali Midha, Melissa Ng, Simon J. Harrison, Aaron S. Kesselheim, Benjamin W. Teh	2023	42
12	A real‐world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple‐myeloma patients British Journal of Haematology ·Sarah Bird, Charlotte Pawlyn, Susanna Nallamilli, Priya Sriskandarajah, Martin Kaiser, Kwee Yong, Rakesh Popat, Neil Rabin, Kevin Boyd	2020	7
13	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis British Journal of Haematology ·Oliver C. Cohen, Faye Sharpley, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Marianna Fontana, Carol Whelan, Ana Martinez–Naharro, Charalampia Kyriakou, Neil Rabin, Rakesh Popat, Kwee Yong, Simon Cheesman, Raakhee Shah, Philip N. Hawkins, Ashutosh Wechalekar	2020	28
14	Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design British Journal of Cancer ·Dimitrios A. Koutoukidis, Joanne Land, Allan Hackshaw, Małgorzata Heinrich, Orla McCourt, Rebecca J. Beeken, Stephanie Philpott, Dunnya De‐Silva, Ali Rismani, Neil Rabin, Rakesh Popat, Charalampia Kyriakou, Xenofon Papanikolaou, Atul Mehta, Bruce Paton, Abigail Fisher, Kwee Yong	2020	42
15	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy British Journal of Haematology ·Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Julian D. Gillmore, Kwee Yong, Neil Rabin, Rakesh Popat, Charalampia Kyriakou, Sarah Worthington, Faye Sharpley, Mark Smith, Raakhee Shah, Simon Cheesman, Philip N. Hawkins, Ashutosh Wechalekar	2019	36
16	Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial The Lancet Oncology ·Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Larry D. Anderson, Heather J. Sutherland, Kwee Yong, Axel Hoos, M Gorczyca, Soumi Lahiri, Zangdong He, Daren Austin, Joanna Opalinska, Adam D. Cohen	2018	192
17	REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA UCL Discovery (University College London) ·Monica Ziff, Simon Cheesman, Charalampia Kyriakou, A. Mehta, Xanthos Papanikolaou, Neil Rabin, Ashu Wechalekar, Kwee Yong, Rakesh Popat	2017	5
18	Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts Blood ·Jason Kaplan, Leo I. Gordon, Alessandro Rambaldi, Giuseppe Gritti, Rakesh Popat, Howard A. Burris, Manish R. Patel, Sumit Madan, Ian Chau, John Radford, Swaminathan P. Iyer, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Shining Wang, Emily Sheldon‐Waniga, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch	2017	1
19	Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response British Journal of Haematology ·Arash Latifoltojar, Margaret Hall‐Craggs, Neil Rabin, Rakesh Popat, Alan Bainbridge, Νικόλαος Δικαίος, Magdalena Sokolska, Ali Rismani, Shirley D’Sa, Shonit Punwani, Kwee Yong	2016	46
20	PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma British Journal of Haematology ·Heather Oakervee, Rakesh Popat, Nicola Curry, Pat Smith, Curly Morris, Mary Drake, Samir Agrawal, Jim Stec, David P. Schenkein, Dixie‐Lee Esseltine, Jamie Cavenagh	2005	235

About Rakesh Popat

Rakesh Popat is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 154 papers that have together received 2.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (129 papers), Protein Degradation and Inhibitors (65 papers), Peptidase Inhibition and Analysis (26 papers), CAR-T cell therapy research (21 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Cancer Treatment and Pharmacology (15 papers), Histone Deacetylase Inhibitors Research (13 papers) and Chronic Lymphocytic Leukemia Research (12 papers). The work is most often cited by research in Hematology (1.9k citations), Oncology (1.4k citations), Genetics (282 citations), Molecular Biology (1.7k citations) and Radiology, Nuclear Medicine and Imaging (410 citations). Rakesh Popat has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Jamie Cavenagh, Heather Oakervee, Kwee Yong, Joanna Opalinska, Nicola Curry, Curly Morris, Dixie‐Lee Esseltine, Mary Drake, Paul G. Richardson and Suzanne Trudel. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, HemaSphere and Blood Cancer Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact